JMS Co

JMS Co Equity

The The Equity of JMS Co (7702.T) as of Nov 2, 2026 is 41.73 B JPY. In the previous year, The Equity was 40.84 B JPY — a change of 2.19% (higher).

Equity

41.73 BJPY

YoY

2.19%

Last updated:

In 2026, JMS Co's equity was 41.73 B JPY, a 2.19% increase from the 40.84 B JPY equity in the previous year.

The JMS Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
31.77 B JPY
Jan 1, 2020
32.34 B JPY
Jan 1, 2021
34.84 B JPY
Jan 1, 2022
36.96 B JPY
Jan 1, 2023
38.53 B JPY
Jan 1, 2024
40.57 B JPY
Jan 1, 2025
40.84 B JPY
Jan 1, 2026
41.73 B JPY
The JMS Co Equity history
YEAREquityYoY
41.73 BJPY+2.19%
40.84 BJPY+0.65%
40.57 BJPY+5.30%
38.53 BJPY+4.25%
36.96 BJPY+6.08%
34.84 BJPY+7.75%
32.34 BJPY+1.80%
31.77 BJPY+1.09%
31.42 BJPY+1.59%
30.93 BJPY+0.46%
30.79 BJPY-2.00%
31.42 BJPY+2.92%
30.53 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JMS Co Stock analysis

What does JMS Co do? JMS Co., Ltd. generates revenue through the manufacture, sale, export, and import of medical devices and pharmaceuticals across its five geographical segments: Japan, Singapore, China, Philippines, and Germany. The company offers a range of products including infusion and nutrition products, dialysis products, surgery products, blood and cell products, and other related items. Key products such as infusion & transfusion sets, syringe pumps, surgical gowns, dialysis kits, peritoneal dialysate, microcatheters, and blood bags are sold to healthcare providers and institutions within these regions. The firm also provides maintenance services and other related services as part of its product portfolio. The company's primary customers are healthcare providers and institutions in Japan, Singapore, China, Philippines, and Germany, where it operates through its five geographical segments. These customers purchase medical equipment and drugs, including specific items like infusion & transfusion sets, dialysis kits, and surgical gowns. The firm's product lines are tailored to meet the needs of hospitals, clinics, and other medical facilities across its operational regions. JMS Co., Ltd. focuses on manufacturing and selling medical equipment and drugs, with a strong emphasis on products such as infusion & transfusion sets, syringe pumps, surgical gowns, and dialysis kits. The company's revenue streams are driven by the sale of these products and the provision of maintenance services. Its geographical segments ensure a diversified market presence, allowing it to serve various healthcare sectors in different countries. JMS Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing JMS Co's Equity

JMS Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding JMS Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating JMS Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

JMS Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in JMS Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about JMS Co stock

The Equity of JMS Co is 41.73 B JPY in 2026.

The Equity of JMS Co changed from 40.84 B JPY to 41.73 B JPY, representing a 2.19% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity JMS Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's JMS Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — JMS Co

All Key Metrics — JMS Co